0001493152-24-001690.txt : 20240108 0001493152-24-001690.hdr.sgml : 20240108 20240108143459 ACCESSION NUMBER: 0001493152-24-001690 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240104 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240108 DATE AS OF CHANGE: 20240108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sigyn Therapeutics, Inc. CENTRAL INDEX KEY: 0001642159 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 472573116 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-55575 FILM NUMBER: 24519681 BUSINESS ADDRESS: STREET 1: 9190 W OLYMPIC BLVD # 263 CITY: BEVERLY HILLS STATE: CA ZIP: 90212 BUSINESS PHONE: 619-368-2000 MAIL ADDRESS: STREET 1: 9190 W OLYMPIC BLVD # 263 CITY: BEVERLY HILLS STATE: CA ZIP: 90212 FORMER COMPANY: FORMER CONFORMED NAME: Reign Resources Corp DATE OF NAME CHANGE: 20200512 FORMER COMPANY: FORMER CONFORMED NAME: Reign Sapphire Corp DATE OF NAME CHANGE: 20150512 8-K 1 form8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): January 4, 2024

SIGYN THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

000-55575

47-2573116

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

2468 Historic Decatur Road
Suite 140
San Diego, California		92106
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: 619.368.2000

Prior address and phone number:

2468 Historic Decatur Road, Suite 140
San Diego, CA		92106
(Address of principal executive offices)		(Zip Code)

619.353.0800

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
None		None		None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On January 4, 2024, Sigyn Therapeutics, Inc. (the “Company”) issued a press release announcing the release of a shareholder letter authored by James A. Joyce, Chairman and Chief Executive Officer of the Company. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Item 7.01 “Regulation FD Disclosure” and Exhibit 99.1 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated January 4, 2024
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SIGYN THERAPEUTICS, INC.

Date: January 8, 2024	By:	/s/ James A. Joyce
		James A. Joyce, Chairman and CEO

EX-99.1 2 ex99-1.htm

Exhibit 99.1

Sigyn Therapeutics Releases Letter to Shareholders

SAN DIEGO, January 4, 2024 — Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announced the release of a shareholder letter authored by Chairman and Chief Executive Officer, Jim Joyce.

Dear Fellow Shareholder,

As a small organization operating in a world with short-term expectations, we have not wavered from making decisions and sacrifices that support our long-term objective to build an enduring organization whose therapies save lives. The goal of this letter is to help you better understand our opportunities, our challenges, and decision-making processes.

Over the past eighteen months, we set the stage for first-in-human studies of Sigyn Therapy^TM and quietly built a foundation for therapeutic devices to enhance the performance of cancer therapies. More specifically, we leveraged industry relationships to redefine our lead treatment indication for Sigyn Therapy^TM and we designed novel devices that offer to overcome the delivery limitations of chemotherapy and immunotherapeutic antibodies to treat cancer. As you will learn, these critically important drug agents are inadequately delivered to intended cancer targets.

Our decision process to develop a new therapy is guided various factors but must include two prerequisites: 1.) the candidate therapy must offer to overcome a clearly defined limitation in healthcare, and 2.) the successful clinical advancement of the candidate would establish a potential competitive advantage that could disrupt the business model of established therapeutic organizations. I urge you to read the entirety of this letter with the hope you concur our product candidates meet these development prerequisites.

However, I first want to provide an update on our proposed underwritten financing. At present, we have an S-1 registration statement on file with the U.S. Securities and Exchange Commission (SEC) (available at www.sec.gov) to support a financing whose proceeds will advance our clinical programs and potentially allow us to meet the exchange listing requirements of the Nasdaq Capital Market. While our S-1 is on file, we remain in a quiet period that limits the information we can release until the SEC staff declares our registration statement to be effective. However, we are permitted to publish factual information that is material to our business.

This process seems to overshadow the extent to which we transformed our business since the initial submission of our S-1 to the SEC. In that submission, our endeavors were solely predicated on the development and clinical advancement of Sigyn Therapy^TM. As reflected in recent S-1 amendments, our endeavors today are comprised of Sigyn Therapy^TM to address pathogen-associated inflammatory disorders, the ImmunePrep^TMplatform to enhance the performance of immunotherapeutic antibodies, ChemoPrep^TM to improve the delivery of chemotherapy, and ChemoPure^TM to reduce chemotoxicity. Furthermore, our clinical plan to advance Sigyn Therapy^TM has evolved to become more expansive and enrollable, with clinical sites and principal investigators now in place for first-in-human studies.

With support from industry colleagues and the steadfast dedication of our team, we established a lineup of therapeutic candidates that is unique within in our industry.

The ImmunePrep^TMPlatform

Immunotherapeutic antibodies to treat cancer are among the most valued assets in global medicine. However, these drugs suffer from a severe limitation. They are poorly delivered to cancer cell targets and as a result, a majority of patients don’t respond to therapy. FACT!

Only a fraction of an antibody dose reaches its cancer cell target, yet a significant portion of the same dose can be sequestered from delivery by circulating decoys that display the target (antigen) binding site of the antibody. Amazingly, with more than 1,000 therapeutic antibodies being evaluated in human studies, there was no strategy to reduce the circulating presence of decoys that block the delivery of these drugs.

In response, we designed the ImmunePrep^TM platform. Mechanistically, ImmunePrep^TM is intended to leverage the use of therapeutic antibodies to create extracorporeal blood purification devices that sweep antibody decoys from the bloodstream prior to the subsequent infusion (normal delivery) of the same therapeutic antibody. We believe this reverse decoy mechanism will increase the availability of antibodies to interact with their intended targets and simultaneously, ImmunePrep^TM devices are expected to extract disease targets from the bloodstream to further improve patient benefit. Our regulatory strategy is initially directed toward the development of ImmunePrep^TM products that incorporate market-cleared antibodies already demonstrated to be safe and effective in human studies.

Regarding my statement of therapeutic antibodies being among the most valued assets in global medicine, consider that Pfizer’s $43 billion acquisition of Seagen, Inc. and Amgen’s $27.8 billion acquisition of Horizon Therapeutics were the highest valued M&A deals of 2023. In both cases, transaction values were driven by market-cleared antibody assets.

Perhaps more revealing were the values placed on clinical-stage (pre-revenue) therapeutic antibody candidates. In this regard, consider Merck’s $10.8 billion acquisition of Prometheus Biosciences and Roche’s $7 billion acquisition of a clinical-stage antibody from Roivant Sciences.

In the backdrop of these M&A transactions, the immune checkpoint antibody Keytruda (Merck) became the world’s best-selling (non-vaccine) drug in 2023 with anticipated revenues of ~$24 billion.

ImmunePrep^TMis a development-stage platform that introduces a device strategy to synergistically enhance the performance of these highly valued drug assets.

ChemoPrep^TM& ChemoPure^TM

Recent scientific publications have reported that only 1% of chemotherapy is successfully delivered to the tumor cell targets of cancer patients. In response, we began to investigate strategies to overcome the delivery limitations of the most commonly administered drug to treat cancer. Inversely, we recognized if 99% of chemotherapy was missing its therapeutic target, then there was an additional need to remove off-target chemotherapy from the bloodstream to reduce toxicity and limit organ damage.

These thoughts, along with some pre-clinical data evolved into a patent submission entitled: “Systems and Methods to Enhance Chemotherapy Delivery and Reduce Toxicity.” This pending patent underlies our therapeutic system comprised of ChemoPrep^TMwhich is intended to enhance the tumor site delivery of chemotherapy and ChemoPure^TM to reduce its toxicity.

To enhance chemotherapy delivery, we designed ChemoPrep^TM to reduce the circulating presence of tumor-derived exosomes (cancer exosomes) that interfere with chemotherapy delivery and contribute to treatment resistance. As might be expected, high concentrations of cancer exosomes in the bloodstream correspond with poor treatment outcomes, whereas low concentrations are associated with more favorable outcomes. As compared to non-cancer subjects, exosome populations are reported to be 10x to 500x higher in the bloodstream of cancer patients.

There is a compelling scientific rationale to reduce the circulating presence of cancer exosomes prior to chemotherapy administration. In this regard, we envision the possibility of improving chemotherapy delivery with lower doses. Such an achievement could contribute to addressing ongoing drug shortages that have limited the availability of chemotherapy to cancer patients.

Post-chemotherapy administration, ChemoPure^TM is intended to reduce treatment toxicity by depleting the presence of off-target chemotherapy from the bloodstream. A reduction in chemotoxicity may also alleviate treatment-related fatigue and temper the long-term health consequences associated with chemotherapy administration.

Sigyn Therapy^TM

We are advancing Sigyn Therapy^TM to treat pathogen-associated inflammatory disorders that are not addressed with FDA approved drugs. Our candidate treatment indications include community-acquired pneumonia, drug-resistant viral & bacterial infections, endotoxemia, and sepsis, the leading cause of hospital deaths in the United States.

Our technology has the following attributes and capabilities:

	●	Sigyn Therapy^TM incorporates a formulation of adsorbent components that have more than 200,000 square meters (~50 acres) of surface area on which to adsorb and remove therapeutic targets from the bloodstream.

	●	In vitro studies have demonstrated the ability of Sigyn Therapy^TM to reduce life-threatening pathogen and inflammatory disease targets from human blood plasma. In these studies, twelve relevant targets, including viral pathogens, bacterial toxins, and inflammatory cytokines were validated. Subsequent animal studies have been conducted at the University of Michigan. GO WOLVERINES!

	●	Sigyn Therapy^TM is highly efficient as the entire circulatory system of a patient can pass through the device ~15-times during a four-hour treatment.

	●	To allow for potential broad-market deployment, we designed Sigyn Therapy^TM for use on the established infrastructure of dialysis and continuous renal replacement machines already located in hospitals and clinics around the world.

We believe the successful clinical advancement of Sigyn Therapy^TM could offer a strategic competitive advantage within the dialysis industry. As such, the treatment protocol of first-in-human studies calls for the enrollment of dialysis dependent end-stage renal disease (ESRD) patients with endotoxemia and concurrent inflammation. These are untreatable conditions associated with cardiovascular disease, the leading cause of ESRD patient deaths. Endotoxemia and inflammation also underly other common causes of ESRD mortality, including viral and bacterial infections that induce sepsis.

A strategy that extended the lives of ESRD patients should be of considerable value to the dialysis industry. Consider that there are more than 550,000 individuals with ESRD in the United States, which results in approximately 85 million dialysis treatments being administered each year. Once on dialysis, the five-year survival rate of an ESRD patient is just 42%. A large percentage of ESRD patients suffer from endotoxemia and/or chronic inflammation. Most are treated by either Fresenius Medical Care or DaVita Kidney Care.

In 2022, Fresenius generated $14.5 billion in revenues through the administration of 31.8 million dialysis treatments to the 208,310 ESRD patients in their North American network. During the same year, DaVita generated $11.6 billion in revenues based on administering 30 million dialysis treatments to the 199,400 ESRD patients in their North American network.

Based on 2022 numbers, extending the life of Fresenius network patients by just one month would be worth ~ $1.2 billion in added revenues to Fresenius, whereas DaVita would add almost $1 billion in revenues per month of extended life of their patients. Fresenius and DaVita also lose revenues when their patients are hospitalized, which is a common occurrence. In this regard, each week of reduced hospitalization is worth ~ $300 million in added revenues for Fresenius and ~$240 million for DaVita.

Our business and clinical strategy to enroll ESRD patients was established with feedback from dialysis industry executives. Furthermore, we leveraged our industry relationships to craft the protocol of our first-in-human clinical studies, to establish multiple clinical site locations, and identify our principal investigators.

To support our proposed study, we have drafted an Investigational Device Exemption (IDE) for submission to the FDA that calls for the enrollment of 12-15 ESRD patients with endotoxemia and concurrent inflammation. In the proposed study, Sigyn Therapy^TMwill be combined in series with each enrolled subjects normally scheduled dialysis treatments. While our primary objective is to demonstrate treatment safety, we will also quantify changes in endotoxin and inflammatory cytokine levels that result from Sigyn Therapy^TMadministration. The successful completion of this study would then set the stage for us to pursue pivotal efficacy studies necessary for market approval.

In closing, we have created an expansive lineup of therapeutic candidates with support from industry colleagues and the steadfast dedication of our team. A team that is not naïve to the challenges of advancing medical devices through FDA. A team focused on building an enduring organization whose therapies save lives.

On behalf of Sigyn’s board of directors and employees, I thank you for your support and belief in our endeavors.

James A. Joyce

Chairman and Chief Executive Officer

January 4, 2024

Cautionary Note Regarding Forward-Looking Statements

This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this summary are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as “may,” “believe,” “anticipate,” “expect,” “intend,” “plan,” “project,” “will,” “projections,” “estimate,” “potentially” or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Sigyn’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences may include, without limitation, the Company’s ability to clinically advance Sigyn Therapy in human studies required for market clearance, the Company’s ability to manufacture Sigyn Therapy, the Company’s ability to raise capital resources, and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and in the Company’s other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this report speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Contact:

Jim Joyce

Chairman, CEO

Phone: 619.353.0800

Email: jj@SigynTherapeutics.com

EX-101.SCH 3 sigy-20240104.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 sigy-20240104_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 sigy-20240104_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Jan. 04, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jan. 04, 2024
Entity File Number	000-55575
Entity Registrant Name	SIGYN THERAPEUTICS, INC.
Entity Central Index Key	0001642159
Entity Tax Identification Number	47-2573116
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2468 Historic Decatur Road
Entity Address, Address Line Two	Suite 140
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92106
City Area Code	619
Local Phone Number	368.2000
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false

XML 7 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001642159 2024-01-04 2024-01-04 iso4217:USD shares iso4217:USD shares false 0001642159 8-K 2024-01-04 SIGYN THERAPEUTICS, INC. DE 000-55575 47-2573116 2468 Historic Decatur Road Suite 140 San Diego CA 92106 619 368.2000 false false false false false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 20 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://sigyntherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm sigy-20240104.xsd sigy-20240104_lab.xml sigy-20240104_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "SIGY", "nsuri": "http://sigyntherapeutics.com/20240104", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "sigy-20240104.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "sigy-20240104_lab.xml" ] }, "presentationLink": { "local": [ "sigy-20240104_pre.xml" ] } }, "keyStandard": 20, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 20 }, "report": { "R1": { "role": "http://sigyntherapeutics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-01-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-01-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001493152-24-001690-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-001690-xbrl.zip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end